A Phase II Study of Pembrolizumab, Olaparib, and Temozolomide in Patients With Glioma
This study is testing a combination of three different cancer-fighting drugs—pembrolizumab, olaparib, and temozolomide—for people with a specific type of brain tumor called a glioma. Researchers want to see if using these medications together is safe and effective when previous treatments have stopped working or the tumor has returned.
You might be eligible if you have a confirmed grade 2 or 3 brain tumor with a specific genetic change that has returned after prior treatment, and your steroid medication dose is stable. There are some health and safety restrictions, such as not having active bleeding in the brain or severe ongoing medical conditions.
If you join the study, you will receive a combination of the study medications while doctors closely monitor your health and how your tumor responds using brain scans. You will not be allowed to take other experimental treatments or standard cancer therapies during this time.
This study is currently recruiting participants at locations in Hartford, Connecticut; Miami, Florida; and Basking Ridge, New Jersey, in the United States.
- 1Tests three medications given together for brain tumors that returned or did not respond to past treatment.
- 2Open to patients with specific genetic features in their grade 2 or 3 brain tumor.
- 3Currently recruiting patients at multiple medical centers in the United States.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.